Protalix BioTherapeutics (PLX) Misses Q2 EPS by 17c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.75 +2.23%
EPS Growth %: -266.7%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: -266.7%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.25), $0.17 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $6.43 million versus the consensus estimate of $8.3 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Ledyard Financial Group adds two directors, three retire
- BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
